Trintellix

Trintellix · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 23, 2026

47 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (80)

Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Jun 30, 2031compositionUS 87226845.0y
Jun 30, 2031compositionUS 87226845.0y
Jun 30, 2031compositionUS 87226845.0y
Jun 30, 2031compositionUS 87226845.0y
Dec 15, 2027patentUS 11458134*PED1.4y
Dec 15, 2027patentUS 11458134*PED1.4y
Dec 15, 2027patentUS 11458134*PED1.4y
Dec 15, 2027patentUS 11458134*PED1.4y
Dec 15, 2027patentUS 8969355*PED1.4y
Dec 15, 2027patentUS 8969355*PED1.4y
Dec 15, 2027patentUS 8969355*PED1.4y
Dec 15, 2027patentUS 8969355*PED1.4y
Dec 15, 2027patentUS 9125908*PED1.4y
Dec 15, 2027patentUS 9125908*PED1.4y
Dec 15, 2027patentUS 9125908*PED1.4y
Dec 15, 2027patentUS 9125908*PED1.4y
Dec 15, 2027patentUS 9125909*PED1.4y
Dec 15, 2027patentUS 9125909*PED1.4y
Dec 15, 2027patentUS 9125909*PED1.4y
Dec 15, 2027patentUS 9125909*PED1.4y
Dec 15, 2027patentUS 9125910*PED1.4y
Dec 15, 2027patentUS 9125910*PED1.4y
Dec 15, 2027patentUS 9125910*PED1.4y
Dec 15, 2027patentUS 9125910*PED1.4y
Dec 15, 2027patentUS 9227946*PED1.4y
Dec 15, 2027patentUS 9227946*PED1.4y
Dec 15, 2027patentUS 9227946*PED1.4y
Dec 15, 2027patentUS 9227946*PED1.4y
Dec 15, 2027patentUS 9861630*PED1.4y
Dec 15, 2027patentUS 9861630*PED1.4y
Dec 15, 2027patentUS 9861630*PED1.4y
Dec 15, 2027patentUS 9861630*PED1.4y
Jun 15, 2027formulationUS 11458134343d
Jun 15, 2027formulationUS 11458134343d
Jun 15, 2027formulationUS 11458134343d
Jun 15, 2027formulationUS 11458134343d
Jun 15, 2027method-of-use (U-1668)US 8969355343d
Jun 15, 2027method-of-use (U-1668)US 8969355343d
Jun 15, 2027method-of-use (U-1668)US 8969355343d
Jun 15, 2027method-of-use (U-1668)US 8969355343d
Jun 15, 2027method-of-use (U-2309)US 9125908343d
Jun 15, 2027method-of-use (U-2309)US 9125908343d
Jun 15, 2027method-of-use (U-2309)US 9125908343d
Jun 15, 2027method-of-use (U-2309)US 9125908343d
Jun 15, 2027method-of-use (U-2309)US 9125909343d
Jun 15, 2027method-of-use (U-2309)US 9125909343d
Jun 15, 2027method-of-use (U-2309)US 9125909343d
Jun 15, 2027method-of-use (U-2309)US 9125909343d
Jun 15, 2027method-of-use (U-2309)US 9125910343d
Jun 15, 2027method-of-use (U-2309)US 9125910343d
Jun 15, 2027method-of-use (U-2309)US 9125910343d
Jun 15, 2027method-of-use (U-2309)US 9125910343d
Jun 15, 2027method-of-use (U-1668)US 9227946343d
Jun 15, 2027method-of-use (U-1668)US 9227946343d
Jun 15, 2027method-of-use (U-1668)US 9227946343d
Jun 15, 2027method-of-use (U-1668)US 9227946343d
Jun 15, 2027method-of-use (U-1668)US 9861630343d
Jun 15, 2027method-of-use (U-1668)US 9861630343d
Jun 15, 2027method-of-use (U-1668)US 9861630343d
Jun 15, 2027method-of-use (U-1668)US 9861630343d
Dec 17, 2026patentUS 7144884*PED163d
Dec 17, 2026patentUS 7144884*PED163d
Dec 17, 2026patentUS 7144884*PED163d
Dec 17, 2026patentUS 7144884*PED163d
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884

FDA exclusivities (8)

Feb 23, 2027PEDPediatric (6mo bonus)231d
Feb 23, 2027PEDPediatric (6mo bonus)231d
Feb 23, 2027PEDPediatric (6mo bonus)231d
Feb 23, 2027PEDPediatric (6mo bonus)231d
Aug 23, 2026M-232Method (3y)47d
Aug 23, 2026M-232Method (3y)47d

vortioxetine hydrobromide

indications

all catalysts(0)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (80)

FDA exclusivities (8)